Polymorphisms in the hMSH2 gene and the risk of primary lung cancer.
Polymorphisms in the DNA repair genes may be associated with differences in the capacity to repair DNA damage, and so this can influence an individual's susceptibility to lung cancer. To test this hypothesis, we investigated the association of hMSH2 -118T>C, IVS1+9G>C, IVS10+12A>G, and IVS12-6T>C genotypes and their haplotypes with the risk of lung cancer in a Korean population. The hMSH2 genotypes were determined in 432 lung cancer patients and in 432 healthy controls who were frequency matched for age and gender. The hMSH2 haplotypes were estimated based on a Bayesian algorithm using the Phase program. The presence of at least one IVS10+12G allele was associated with a significantly decreased risk of adenocarcinoma, as compared with the IVS10+12AA genotype [adjusted odds ratio (OR), 0.59; 95% confidence interval (95% CI), 0.40-0.88; P = 0.01], and the presence of at least one IVS12-6C allele was associated with a significantly increased risk of adenocarcinoma, as compared with the IVS12-6TT genotype (adjusted OR, 1.52; 95% CI, 1.02-2.27; P = 0.04). Consistent with the results of the genotyping analysis, the TGGT haplotype with no risk allele was associated with a significantly decreased risk of adenocarcinoma, as compared with the TCAC haplotype with two risk allele [i.e., IVS10+12A and IVS12-6C allele; adjusted OR, 0.49; 95% CI, 0.30-0.78; P = 0.003 and P(c) (Bonferroni corrected P value) = 0.012]. The effect of the hMSH2 haplotypes on the risk of adenocarcinoma was statistically significant in the never smokers and younger individuals (adjusted OR, 0.45; 95% CI, 0.27-0.75; P = 0.002 and P(c) = 0.004; and adjusted OR, 0.44; 95% CI, 0.23-0.85; P = 0.014 and P(c) = 0.028, respectively) but not in the ever-smokers and older individuals. These results suggest that the hMSH2 polymorphisms and their haplotypes may be an important genetic determinant of adenocarcinoma of the lung, particularly in never smokers.
Jung
Chi Young
CY
Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Korea.
Choi
Jin Eun
JE
Park
Jung Min
JM
Chae
Myung Hwa
MH
Kang
Hyo-Gyoung
HG
Kim
Kyung Mee
KM
Lee
Su Jeong
SJ
Lee
Won Kee
WK
Kam
Sin
S
Cha
Seung Ick
SI
Kim
Chang Ho
CH
Han
Sung Beom
SB
Jung
Tae Hoon
TH
Jeon
Su Han
SH
Park
Jae Yong
JY
D000230:Adenocarcinoma / Q000453:epidemiology / Q000209:etiology*; D016022:Case-Control Studies; D004249:DNA Damage / Q000235:genetics*; D005260:Female; D006239:Haplotypes; D006801:Humans; D007723:Korea / Q000453:epidemiology; D008175:Lung Neoplasms / Q000453:epidemiology / Q000209:etiology*; D008297:Male; D008875:Middle Aged; D051718:MutS Homolog 2 Protein / Q000235:genetics*; D016017:Odds Ratio; D011110:Polymorphism, Genetic
C497172:MSH2 protein, human; D051718:MutS Homolog 2 Protein